Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
FDF
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Cefamandole Nafate, Monosodium Salt, (6r-(6alpha,7beta(r*)))-isomer
2. Cefamandole Nafate, Monosodium Salt, 14c-labeled, (6r-(6alpha,7beta,(r*)))-isomer
3. Mandol
1. 42540-40-9
2. Cephamandole Nafate
3. Cefamandol Nafato
4. Kefadol
5. Mandokef
6. O-formylcefamandole Sodium
7. Sodium O-formylcefamandole
8. Cemandil Sodium Salt
9. Cefam
10. Cefamandole Nafate Sodium
11. 8hdo7941do
12. Chebi:3481
13. Cefamandole Formate Sodium Salt
14. Cefaseptolo
15. Lampomandol
16. Bergacef
17. Mandolsan
18. Neocefal
19. Pavecef
20. Cedol
21. Cefamandole Nafate [usan]
22. Ncgc00183035-01
23. Lilly 106223
24. Cefamandol Nafato [spanish]
25. Unii-8hdo7941do
26. Kefandol
27. Cemandil Sodium
28. Einecs 255-877-4
29. Mandol (tn)
30. Mfcd00864877
31. Nsc 299588
32. Cefamandole Nafate [usan:usp:inn:ban]
33. Cefamandole Formate Sodium
34. Cefamandole Nafate, 97%
35. Cefamandole Nafate (usp)
36. Dsstox_cid_2751
37. Chembl1618
38. Dsstox_rid_76715
39. Dsstox_gsid_22751
40. Schembl181311
41. Cefamandole Nafate [mi]
42. Dtxsid2022751
43. Cefamandole Nafate [vandf]
44. Cefamandole Nafate [mart.]
45. Cefamandole Nafate [usp-rs]
46. Cefamandole Nafate [who-dd]
47. Hy-b1166
48. Tox21_113487
49. Akos015895550
50. Akos015961133
51. Ac-1642
52. Ccg-269787
53. Cs-4768
54. Gs-3575
55. Cefamandole Nafate [orange Book]
56. Cefamandole Nafate [ep Monograph]
57. Cefamandole Nafate [usp Impurity]
58. As-12360
59. Cas-42540-40-9
60. C-2464
61. C08102
62. D00909
63. Q27106102
64. Cefamandole Nafate, Antibiotic For Culture Media Use Only
65. 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 7-(((formyloxy)phenylacetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, Monosodium Salt, (6r-(6.alpha.,7.beta.(r*)))
66. 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 7-(((formyloxy)phenylacetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, Monosodium Salt, (6r-(6alpha,7beta(r*)))-
67. Sodium (6r,7r)-7-((r)-2-(formyloxy)-2-phenylacetamido)-3-((1-methyl-1h-tetrazol-5-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
68. Sodium (6r,7r)-7-[(2r)-2-(formyloxy)-2-phenylacetamido]-3-{[(1-methyl-1h-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
69. Sodium (6r,7r)-7-[[(2r)-2-formyloxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
70. Sodium (6r,7r)-7-{[(2r)-2-(formyloxy)-2-phenylacetyl]amino}-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
71. Sodium (6r,7r)-7-{[(2r)-2-(formyloxy)-2-phenylacetyl]amino}-3-{[(1-methyl-1h-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
72. Sodium (6r-(6alpha,7beta(r*)))-7-(((formyloxy)phenylacetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
73. Sodium 7beta-[(2r)-2-(formyloxy)-2-phenylacetamido]-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylate
74. Sodium(6r,7r)-7-(r)-mandelamido-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate Formate(ester)
Molecular Weight | 512.5 g/mol |
---|---|
Molecular Formula | C19H17N6NaO6S2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 9 |
Exact Mass | 512.05486891 g/mol |
Monoisotopic Mass | 512.05486891 g/mol |
Topological Polar Surface Area | 210 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 844 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Cefamandole Nafate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cefamandole Nafate, including repackagers and relabelers. The FDA regulates Cefamandole Nafate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cefamandole Nafate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cefamandole Nafate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cefamandole Nafate supplier is an individual or a company that provides Cefamandole Nafate active pharmaceutical ingredient (API) or Cefamandole Nafate finished formulations upon request. The Cefamandole Nafate suppliers may include Cefamandole Nafate API manufacturers, exporters, distributors and traders.
click here to find a list of Cefamandole Nafate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cefamandole Nafate DMF (Drug Master File) is a document detailing the whole manufacturing process of Cefamandole Nafate active pharmaceutical ingredient (API) in detail. Different forms of Cefamandole Nafate DMFs exist exist since differing nations have different regulations, such as Cefamandole Nafate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cefamandole Nafate DMF submitted to regulatory agencies in the US is known as a USDMF. Cefamandole Nafate USDMF includes data on Cefamandole Nafate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cefamandole Nafate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cefamandole Nafate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Cefamandole Nafate Drug Master File in Korea (Cefamandole Nafate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cefamandole Nafate. The MFDS reviews the Cefamandole Nafate KDMF as part of the drug registration process and uses the information provided in the Cefamandole Nafate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Cefamandole Nafate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cefamandole Nafate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Cefamandole Nafate suppliers with KDMF on PharmaCompass.
Cefamandole Nafate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cefamandole Nafate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cefamandole Nafate GMP manufacturer or Cefamandole Nafate GMP API supplier for your needs.
A Cefamandole Nafate CoA (Certificate of Analysis) is a formal document that attests to Cefamandole Nafate's compliance with Cefamandole Nafate specifications and serves as a tool for batch-level quality control.
Cefamandole Nafate CoA mostly includes findings from lab analyses of a specific batch. For each Cefamandole Nafate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cefamandole Nafate may be tested according to a variety of international standards, such as European Pharmacopoeia (Cefamandole Nafate EP), Cefamandole Nafate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cefamandole Nafate USP).
LOOKING FOR A SUPPLIER?